echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > GUT: Does Sofosbuvir/Vipatavir combined with low-dose ribavirin benefit patients with hepatitis C and renal impairment?

    GUT: Does Sofosbuvir/Vipatavir combined with low-dose ribavirin benefit patients with hepatitis C and renal impairment?

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chronic hepatitis C virus (HCV) infection is associated with an increased risk of chronic kidney disease (CKD)


    Infection immune blood vessel

    If chronic HCV infection is not treated, the survival and quality of life of patients with severe renal impairment will be greatly affected


    The emergence of direct-acting antiviral drugs (DAAs) without interferon (IFN) has transformed the treatment mode of HCV because of its high sustained virological response (SVR) rate and excellent patient tolerance.


    At present, regarding the effects of sofosbuvir/velpatasvir (sofosbuvir/velpatasvir, SOF/VEL) combined or not combined with low-dose ribavirin (RBV) on chronic hepatitis C virus (HCV) infection and severe renal damage ( RI) Patients have limited real-world effectiveness and safety data


    The performance of SOF/VEL with or without low-dose RBV in patients with chronic kidney disease stage 4 or 5 HCV infection SOF/VEL with or without the performance of low-dose RBV in patients with chronic kidney disease stage 4 or 5 HCV infection

    In this trial, 191 patients with liver disease in the compensatory phase (n=181) and decompensated phase (n=10) received SOF/VEL alone (400/100mg/day) or SOF/VEL and low-dose RBV ( 200mg/day) treatment for 12 weeks and retrospective recruitment in 15 academic centers in Taiwan


    12

    Experimental design flow chart

    Experimental design flow chart Experimental design flow chart

    The results showed that the SVR 12 rate of EP and PP analysis was 94.


    12 In patients with compensated liver disease, through EP and PP analysis, SVR 12 rates were 95.


    Among the 20 serious adverse events (AEs), none was judged to be related to SOF/VEL or RBV.


    SOF/VEL combined or not combined with low-dose RBV is effective and well tolerated in patients with severe RI infected by HCV SOF/VEL combined or not combined with low-dose RBV is effective and well tolerated in patients with severe RI infected by HCV

     

    Original source:

    Original source:

    Chen-Hua Liu et al.


    Chen-Hua Liu et al.


     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.